yttrium radioisotopes and Lymphoma, Follicular
yttrium radioisotopes has been researched along with Lymphoma, Follicular in 50 studies
Research
Studies (50)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 22 (44.00) | 29.6817 |
2010's | 24 (48.00) | 24.3611 |
2020's | 4 (8.00) | 2.80 |
Authors
Authors | Studies |
---|---|
De Filippi, R; Hess, G; Keller, U; Lerch, K; Lindén, O; Neumeister, P; Peuker, CA; Pezzutto, A; Pinto, A; Rieger, K; Scholz, CW; Stroux, A; Viardot, A | 1 |
Alhaj Moustafa, M; Hoppe, BS; Jiang, J; Peterson, J; Tun, HW; Wiseman, GA; Witzig, TE | 1 |
Alhaj Moustafa, M; Borah, BJ; Cerhan, JR; Dholakia, R; Hoppe, BS; Jiang, L; Li, K; Moriarty, JP; Peterson, J; Tun, HW; Witzig, TE | 1 |
Buck, AK; Dreher, N; Einsele, H; Higuchi, T; Kraus, S; Rasche, L; Samnick, S; Serfling, SE; Werner, RA | 1 |
Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
Berdel, WE; Görlich, D; Hartmann, W; Kerkhoff, A; Lenz, G; Schliemann, C; Schmidt, LH; Schulze, A; Spukti, EU; Wardelmann, E | 1 |
Baillet, C; Barthélémy, C; Bigot, P; Décaudin, B; Dekyndt, B; Fulcrand, J; Huglo, D; Malek, E; Morschhauser, F; Odou, P; Simon, N | 1 |
Bischof-Delaloye, A; Botto, B; Hagenbeek, A; Kylstra, JW; Morschhauser, F; Radford, J; Rohatiner, AZ; Salles, G; Soubeyran, P; Tilly, H; Van Hoof, A; van Putten, WL | 1 |
Hagenbeek, A | 1 |
Bardies, M; Bates, AT; Bayne, M; Bodet-Milin, C; Huglo, D; Illidge, TM; Jardin, F; Kraeber-Bodere, F; Le Gouill, S; Malek, E; Mayes, S; Morschhauser, F; Pettengell, R; Radford, JA; Ryder, WD; Tipping, J; Zivanovic, M | 1 |
Razzak, M | 1 |
Botto, B; Carella, AM; Cascavilla, N; Ciabatti, E; Ciochetto, C; Fraternali Orcioni, G; Galimberti, S; Guolo, F; Ibatici, A; Nati, S; Orciuolo, E; Petrini, M; Pica, GM; Vitolo, U; Zinzani, PL | 1 |
Andrade-Campos, MM; Baringo, T; Giraldo, P; Grasa, JM; Lopez-Gómez, L; Montes-Limón, AE; Soro-Alcubierre, G | 1 |
Berkova, Z; Braun, FK; Fanale, MA; Feng, L; Fowler, N; Kwak, LW; Mathur, R; McLaughlin, P; Neelapu, SS; Pro, B; Romaguera, JE; Samaniego, F; Sehgal, L; Selvaraj, V; Shah, JJ | 1 |
Carella, AM; Ceccherini-Nelli, L; Ciabatti, E; Focosi, D; Galimberti, S; Macera, L; Maggi, F; Petrini, M; Pistello, M | 1 |
Eickhoff, J; Kahl, BS; Kristinsdottir, T; Meyer, CM; Peterson, C; Rajguru, S; Traynor, AM | 1 |
Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
Bondiau, PY; Broglia, JM; Carrier, P; Darcourt, J; Fontana, X; Gressin, R; Lepeu, G; Peyrade, F; Peyrottes, I; Slama, B; Thyss, A; Triby, C | 1 |
Chen, J; Fani, M; Forrer, F; Lohri, A; Maecke, HR; Moldenhauer, G; Müller-Brand, J; Powell, P | 1 |
Goff, L; Hagenbeek, A; Iqbal, S; Kuhlmann, J; Kunz, M; Lister, A; Louton, T; Morschhauser, F; Putz, B; Rohatiner, A; Summers, K | 1 |
Baldini, R; Cicone, F; Cox, MC; Russo, E; Scopinaro, F; Tofani, A; Torelli, F | 1 |
Bellò, M; Bertagna, F; Botto, B; Derenzini, E; Fanti, S; Fonti, C; Huglo, D; Lopci, E; Morschhauser, F; Santi, I; Savelli, G; Zinzani, P | 1 |
Burdick, MJ; Macklis, R; Neumann, D; Pohlman, B; Reddy, CA; Tendulkar, RD | 1 |
Castellucci, P; Fanti, S; Fonti, C; Lopci, E; Maffione, AM; Montini, G; Rubello, D; Santi, I; Stefoni, V; Tani, M; Zinzani, P | 1 |
Carpaneto, A; Cicone, F; Delaloye, AB; Ketterer, N; Prior, JO; Russo, E; Scopinaro, F | 1 |
Leahy, MF; Turner, JH | 1 |
Assisi, D; D'Andrea, M; Dessanti, L; Maini, CL; Petti, MC; Pisani, F; Sciuto, R | 1 |
Argnani, L; Baccarani, M; Broccoli, A; Cavalieri, E; De Renzo, A; Derenzini, E; Fanti, S; Fina, M; Gandolfi, L; Montini, GC; Pellegrini, C; Pileri, S; Pulsoni, A; Quirini, F; Rossi, M; Scopinaro, F; Stefoni, V; Tani, M; Torelli, F; Zinzani, PL | 1 |
Illidge, T; Morschhauser, F | 1 |
Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P | 1 |
Alousi, AM; Anderlini, P; Bashir, Q; Champlin, RE; Ciurea, S; de Lima, M; Erwin, WD; Fowler, N; Gulbis, AM; Hosing, C; Kebriaei, P; Khouri, IF; Korbling, M; Macapinlac, HA; Medeiros, LJ; Neelapu, SS; Popat, UR; Saliba, RM; Samaniego, F; Samuels, BI; Valverde, R | 1 |
Doksansky, H; Flowers, CR; Garrett, G; Kucuk, RA; Nastoupil, LJ; Rose, AC; Seward, M; Shenoy, PJ | 1 |
Cripe, L; Czuczman, MS; Emmanouilides, C; Flinn, IW; Gordon, LI; Multani, PS; Olejnik, T; Saleh, MN; White, CA; Wiseman, G; Witzig, TE | 1 |
Ansell, SM; Habermann, TM; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
Bartlett, N; Czuczman, M; Darif, M; Emmanouilides, C; Gordon, LI; Joyce, R; Molina, A; Pohlman, B; Theuer, C; Vo, K; White, C; Wiseman, G; Witzig, T | 1 |
Bartlett, N; Gordon, L; Molina, A; Murray, J; Schilder, R; Spies, S; Wang, H; White, C; Wiseman, G; Witzig, T | 1 |
Avril, N; Degirmenci, B; Jacobs, S; Joyce, JM; McCook, B | 1 |
de Nully Brown, P; Hansen, M; Jurlander, J; Lindén, O | 1 |
Chatal, JF | 1 |
DeMonaco, NA; Jacobs, SA; Joyce, J; McCarty, KS | 1 |
Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Markovic, SN; Micallef, IN; Porrata, LF; Ristow, K; Tuinistra, N; Witzig, TE | 1 |
Buriankova, E; Drymlova, J; Indrak, K; Kubova, Z; Kucerova, L; Myslivecek, M; Papajik, T; Prochazka, V; Raida, L | 1 |
Fontana, X; Italiano, A; Peyrade, F; Peyrottes, I; Thyss, A | 1 |
Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
Jacobs, SA; Jankowitz, R; Joyce, J | 1 |
Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
Boni, G; Cecconi, N; Focosi, D; Galimberti, S; Orciuolo, E; Petrini, M | 1 |
Belanger, R; Berlfein, JR; Dahlbom, M; Ding, E; Dunn, WL; Erwin, W; Grillo-López, AJ; Karvelis, K; Raubitschek, A; Schultheiss, T; Silverman, DH; Spies, S; Stabin, M; White, CA; Wiseman, GA; Witzig, TE | 1 |
Bartlett, NL; Cabanillas, F; Czuczman, MS; Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Joyce, R; Multani, P; Padre, N; Pohlman, BL; White, CA; Wiseman, GA; Witzig, TE | 1 |
Reviews
3 review(s) available for yttrium radioisotopes and Lymphoma, Follicular
Article | Year |
---|---|
Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.
Topics: Aged; Antibodies, Monoclonal; Bone Marrow Transplantation; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Shock, Septic; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Radioimmunotherapy in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Humans; Lymphoma, Follicular; Mice; Radioimmunotherapy; Recurrence; Remission Induction; Risk Factors; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Yttrium Radioisotopes | 2011 |
A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, Follicular; Radioimmunotherapy; Yttrium Radioisotopes | 2012 |
Trials
21 trial(s) available for yttrium radioisotopes and Lymphoma, Follicular
Article | Year |
---|---|
A new pharmacokinetic model for
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Models, Biological; Radiometry; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2018 |
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Humans; International Cooperation; Kaplan-Meier Estimate; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Radioimmunotherapy; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes | 2013 |
Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
Topics: Adult; Aged; Antibodies, Monoclonal; Dose Fractionation, Radiation; Female; Humans; International Cooperation; Lymphoma, Follicular; Male; Middle Aged; Radioimmunotherapy; Remission Induction; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pilot Projects; Radiation Injuries; Radioimmunotherapy; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2014 |
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Radiation Injuries; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Pilot Projects; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes | 2009 |
Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gene Order; Genes, bcl-2; Humans; Immunoglobulin Heavy Chains; Lymphoma, Follicular; Male; Middle Aged; Polymerase Chain Reaction; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome; Yttrium Radioisotopes | 2009 |
External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Blood Cell Count; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Platelet Count; Positron-Emission Tomography; Radiotherapy; Radiotherapy Dosage; Recurrence; Tomography, X-Ray Computed; Tumor Burden; Yttrium Radioisotopes | 2011 |
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2011 |
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prospective Studies; Radioimmunotherapy; Rituximab; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2012 |
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Radiopharmaceuticals; Rituximab; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2011 |
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Rituximab; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Cell Line, Transformed; Clinical Trials as Topic; Disease Progression; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Radioimmunotherapy; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2004 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2008 |
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bone Marrow; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiometry; Rituximab; Yttrium Radioisotopes | 2000 |
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radionuclide Imaging; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Other Studies
26 other study(ies) available for yttrium radioisotopes and Lymphoma, Follicular
Article | Year |
---|---|
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Topics: Aged; Antibodies, Monoclonal; Follow-Up Studies; Humans; Lymphoma, Follicular; Middle Aged; Neoplasm Staging; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2022 |
Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.
Topics: Antibodies, Monoclonal; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Radioimmunotherapy; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2022 |
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Topics: Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2023 |
Theranostics in Hematooncology.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Positron Emission Tomography Computed Tomography; Precision Medicine; Radioimmunotherapy; Yttrium Radioisotopes | 2023 |
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes | 2017 |
Topics: Adult; Aged; Antibodies, Monoclonal; Combined Modality Therapy; Female; Humans; Immunoconjugates; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2018 |
Haematological cancer: Radioimmunotherapy--time to be upfront and fractionated?
Topics: Antibodies, Monoclonal; Female; Humans; Lymphoma, Follicular; Male; Yttrium Radioisotopes | 2014 |
Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antigens, Neoplasm; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neutropenia; Quality of Life; Radioimmunotherapy; Remission Induction; Rituximab; Thrombocytopenia; Yttrium Radioisotopes | 2014 |
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy; Clinical Trials as Topic; Humans; JC Virus; Lymphoma, Follicular; Polyomavirus Infections; Radiopharmaceuticals; Rituximab; Tumor Virus Infections; Virus Activation; Yttrium Radioisotopes | 2014 |
Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radioimmunotherapy; Rituximab; Treatment Outcome; Tumor Burden; Wisconsin; Yttrium Radioisotopes | 2014 |
Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: efficacy and safety in a routine setting.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Radioimmunotherapy; Retrospective Studies; Rituximab; Yttrium Radioisotopes | 2009 |
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiography; Radioimmunotherapy; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2010 |
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2010 |
Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Radioimmunotherapy; Recurrence; Retrospective Studies; Rituximab; Yttrium Radioisotopes | 2011 |
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Rituximab; Vidarabine; Yttrium Radioisotopes | 2011 |
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Treatment Outcome; Yttrium Radioisotopes | 2002 |
[Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi].
Topics: Antibodies, Monoclonal; Antigens, CD20; Chelating Agents; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.
Topics: Antibodies, Monoclonal; Antigens, CD20; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Positron-Emission Tomography; Radioimmunotherapy; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2005 |
[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2005 |
Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective.
Topics: Antibodies, Monoclonal; Europe; Humans; Lymphoma, Follicular; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Yttrium Radioisotopes | 2006 |
Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Diagnosis, Differential; Dose-Response Relationship, Radiation; Humans; Laryngeal Neoplasms; Lung Neoplasms; Lymphoma, Follicular; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiation Pneumonitis; Radioimmunotherapy; Recurrence; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphocyte Count; Lymphoma, Follicular; Male; Middle Aged; Prognosis; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Yttrium Radioisotopes | 2007 |
Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Lymphoma, Follicular; Radioimmunotherapy; Recurrence; Rituximab; Yttrium Radioisotopes | 2007 |
Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment.
Topics: Aged; Antibodies, Monoclonal; Humans; Lymphoma, Follicular; Male; Neoplasm Recurrence, Local; Radioimmunotherapy; Retreatment; Yttrium Radioisotopes | 2007 |
Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.
Topics: Anaphylaxis; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; Humans; Lymphoma, Follicular; Male; Middle Aged; Radioimmunotherapy; Yttrium Radioisotopes | 2008 |
Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma.
Topics: Antibodies, Monoclonal; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Middle Aged; Neoplasms, Second Primary; Radioimmunotherapy; Yttrium Radioisotopes | 2008 |